Novo Nordisk closer to launch of prize asset in Europe following new approval

Changes in the pricing strategy for Novo Nordisk's new drug hope Ozempic have caused larger regulatory problems in the EU than expected, and have impacted the launch in European countries. But the pharmaceutical company has just received an important approval, which will enable a launch in the second half of the year.

Photo: /Ritzau Scanpix/Linda Kastrup

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles